GLENMARK PHARMACEUTICALS LTD. - Enrollment Begins of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis
04 Nov 2014
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated November 04, 2014, titled "Enrollment Begins of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis".
Source:
BSE India